J. Louw

发表

Title : Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

David S. K. Lu, H. Vargas, H. Scher, 2017 .

Non‐steroidal anti‐inflammatory drug toxicity in the upper gastrointestinal tract

P. Brooks, J. Sollano, J. Louw, 2000, Journal of gastroenterology and hepatology.

Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells

David S. K. Lu, J. Schlom, M. Landers, 2015, Journal of circulating biomarkers.

Androgen receptor expression on circulating tumor cells in metastatic breast cancer

Yipeng Wang, N. Ueno, J. Reuben, 2017, PloS one.

Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival

David S. K. Lu, S. Makani, D. Boffa, 2017, Cancer Epidemiology, Biomarkers & Prevention.

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.

David S. K. Lu, H. Scher, M. Fleisher, 2017, European urology.

Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC).

H. Scher, R. Krupa, J. Louw, 2014 .

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2016, JAMA oncology.

Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC).

H. Scher, D. Danila, R. Krupa, 2014 .

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2017, Cancer research.

Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer

S. Tomlins, A. McDaniel, R. Ferraldeschi, 2017, BJU international.

Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer.

S. Tomlins, T. Morgan, F. Feng, 2019, JCO precision oncology.

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer

H. Beltran, J. Mosquera, H. Scher, 2015, Clinical Cancer Research.

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

L. Amler, Yibing Yan, R. Ferraldeschi, 2015, British Journal of Cancer.

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

David S. K. Lu, Yipeng Wang, T. Friedlander, 2016, BMC Cancer.

Barrett's oesophagus: mucin composition, neuroendocrine cells, p53 protein, cellular proliferation and differentiation.

K. Jaskiewicz, J. Louw, N. Anichkov, 1994, Anticancer research.

AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.

David S. K. Lu, H. Scher, Yipeng Wang, 2016 .

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.

David S. K. Lu, T. Friedlander, P. Paris, 2015 .

Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.

M. Rubin, H. Beltran, J. Mosquera, 2015 .

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

David S. K. Lu, Yipeng Wang, T. Friedlander, 2016, BMC Cancer.